Therapeutic Class Overview
Bile Acid Sequestrants

Therapeutic Class

- **Overview/Summary:** The major action of the bile acid sequestrants in modifying lipids is through binding to bile acids in the intestine causing an interruption of their reabsorption. This reduction leads to feedback regulation to increase the conversion of cholesterol to bile acids. The major action of these agents is to reduce low density lipoprotein cholesterol (LDL-C) specifically; therefore, use of a bile acid sequestrant is effective in patients with mild to moderate elevations of LDL-C.[1,2] When administered as monotherapy these agents have the potential to reduce LDL-C by 10 to 24%.[2] Bile acid sequestrants are also effective as add on therapy in patients with markedly elevated LDL-C who are already receiving a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) or niacin.[1,2] According to treatment guidelines, in patients who require LDL-C lowering and who do not achieve lipid goals with the use of a statin alone, consideration should be given to either increasing the dose of the statin or to adding a bile acid sequestrant or niacin to treatment.[1] Bile acid sequestrants can also be added to statins for the treatment of heterozygous familial hypercholesterolemia, and they are recognized as the therapy of choice for the management of pruritus associated with primary biliary cirrhosis.[3,4] There are three bile acid sequestrants available including cholestyramine (Prevalite®, Questran®, Questran Light®), colesevelam (Welchol®) and colestipol (Colestid®, Flavored Colestid®). All of the agents are Food and Drug Administration (FDA)-approved for adjunct treatment in patients with hypercholesterolemia.[5-9] Cholestyramine is also FDA-approved for relief of pruritus associated with partial biliary obstruction.[5,6] Colesevelam is also FDA-approved for use as monotherapy in children 10 to 17 years of age for the treatment of heterozygous familial hypercholesterolemia and as adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes.[9] Cholestyramine and colestipol are both available as powders (colestipol is available in two flavors) to be mixed with water or juice, and are typically administered once or twice daily with meals.[5-8] Colestipol is also available as a tablet (Colestid®).[7,8] Colesevelam is also available as a powder and as a tablet, and is typically administered once or twice daily.[9] Colesevelam is more potent compared to either cholestyramine or colestipol.[1] In addition, colesevelam may be more easily administered and better tolerated compared to the other agents.[1,2] All bile acid sequestrants are available generically, with the exception of colesevelam (Welchol®).

Table 1. Current Medications Available in the Therapeutic Class[5-9]

Generic (Trade Name)	Food and Drug Administration-Approved Indications	Dosage Form/ Strength	Generic Availability
Cholestyramine (Prevalite®*, Questran®*, Questran Light®*)	Adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia who do not respond adequately to diet†, relief of pruritus associated with partial biliary obstruction‡	Powder: 4 g	✔
Colesevelam (Welchol®)	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, adjunct to diet and exercise to reduce elevated low density lipoprotein cholesterol levels in adults with primary hyperlipidemia as monotherapy or in combination with a statin, monotherapy or in combination with a statin to reduce low density lipoprotein cholesterol levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia§	Powder: 3.75 g Tablet: 625 mg	-
Colestipol (Colestid®*, Flavored Colestid®*)	Adjunctive therapy to diet for the reduction of elevated serum cholesterol and low density lipoprotein cholesterol in patients with primary hypercholesterolemia who do not respond	Granules: 5 g Powder:	✔

Generic (Trade Name)	Food and Drug Administration-Approved Indications	Dosage Form/ Strength	Generic Availability
	adequately to diet*	5 g Tablet: 1 g	

*Generic available in at least one dosage form and/or strength.
†May be useful to lower low density lipoprotein cholesterol (LDL-C) levels in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
‡Has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit elevated cholesterol as part of their disease.
§If after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present in the pediatric patient.

Evidence-based Medicine

- Clinical trials have consistently demonstrated the "superiority" of bile acid sequestrants over placebo in the management of hyperlidpidemia.[10-19] In line with current clinical guidelines, results demonstrated that the addition of a bile acid sequestrant to another lipid lowering agent has the potential to produce further reductions in low density lipoprotein cholesterol levels compared to monotherapy with either of the agents.[17-21]
- The Lipid Research Clinical Coronary Primary Prevention trial demonstrated that compared to placebo, treatment with cholestyramine reduced the risk of coronary heart disease death and/or nonfatal myocardial infarction in asymptomatic males with primary hypercholesterolemia (P<0.05).[22,23]
- Several placebo-controlled trials have demonstrated the safety and efficacy of colesevelam as adjunct therapy in adults with type 2 diabetes. Significant reductions in glycosylated hemoglobin (HbA_{1c}) levels were observed when colesevelam was added to stable oral antidiabetic treatment regimens. A small (N=169), 16-week trial demonstrated that least squares mean reductions in HbA_{1c} levels with colesevelam were comparable to either thiazolidinediones or dipeptidyl peptidase 4 inhibitors when added to background metformin therapy.[24-31]
- In a Cochrane Review of six randomized controlled trials, the addition of colesevelam to other hypoglycemic agents significantly reduced HbA_{1c} compared to placebo (mean difference, -0.5%; P<0.00001). In addition, colesevelam with add-on hypoglycemic agents demonstrated a significant reduction in fasting plasma glucose compared to placebo (mean difference, -15 mg/dL; P<0.0001).[32]

Key Points within the Medication Class

- According to Current Clinical Guidelines:
  - Therapeutic lifestyle changes remain an essential modality in the management of patients with hypercholesterolemia.[1,3,33]
  - In general, hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) are considered first-line therapy for decreasing low density lipoprotein cholesterol (LDL-C) levels. If after six weeks, lipid goals are not achieved with statin monotherapy, a dosage increase or the addition of a bile acid sequestrant or niacin should be considered.[1]
  - Statins are also considered first-line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy.[3]
  - Bile acid sequestrants are recognized as the therapy of choice for the management of pruritus associated with primary biliary cirrhosis.[4]
  - In the management of patients with diabetes, the American Association of Clinical Endocrinologists note that colesevelam may provide a possible benefit or few adverse events when given as part of dual or triple therapy in addition to metformin in patients with a glycosylated hemoglobin of ≥7.5%.[34]
  - In general, the American Diabetes Association recommends that a statin be added to lifestyle therapy, regardless of baseline lipid levels, in patients with diabetes. If maximally tolerated doses of statins fail to significantly lower LDL-C (<30% reduction from baseline), no strong evidence exists that combination therapy should be used. Niacin, fenofibrate, ezetimibe, and bile acid sequestrants offer additional LDL-C lowering compared to statins alone; however,

there is no evidence that combination therapy provides a significant cardiovascular disease risk reduction over statin therapy alone.[35]

- Other Key Facts:
  - All of the bile acid sequestrants are available as a powder, while colesevelam and colestipol are also available as a tablet.
  - All bile acid sequestrants are administered once or twice daily.
  - Cholestyramine and colesevelam have additional Food and Drug Administration-approved indications other than management of hypercholesterolemia.
  - Colesevelam is the most potent bile acid sequestrant and may be more easily administered and better tolerated compared to the other agents.[1,2]
  - Cholestyramine and colestipol are available generically.

References

1. National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, 2002 [guideline on the internet]. NCEP. 2002 [cited 2013 Jul 22]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
2. Rosenson RS. Lipid lowering with drugs other than statins and fibrates. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2013 [cited 2013 Jul 22]. Available from: http://www.utdol.com/utd/index.do.
3. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
4. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergassa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
5. Prevalite® [package insert]. Minneapolis (MN): Upsher-Smith Laboratories, Inc.; 1998 Jan.
6. Questran® and Questran Light® [package insert]. Princeton (NJ): Bristol-Meyers Squibb Company; 2006 May.
7. Flavored Colestid® [package insert]. New York (NY): Pharmacia and Upjohn Company; 2013 Jul.
8. Colestid® [package insert]. New York (NY): Pharmacia and Upjohn Company; 2013 Jul.
9. Welchol® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2012 Jul.
10. Stein EA, Marias AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231-6.
11. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006 Apr;185(2):327-30.
12. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15;97(8):1198-205.
13. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, Davidson MH. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct;76(10):971-82.
14. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AFH, Imholz BPM, Durrington PN, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32(4):615-25.
15. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40.
16. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
17. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 Oct;158(2):407-16.
18. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia (abstract). Clin Cardiol. 2001 Jun;24(6):467-74.
19. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr;110(5):352-60.
20. Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med. 1998 May;243(5):373-80.
21. Ballantyne C, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov;26(11):1855-64.
22. No authors listed. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan;251(3):351-64.
23. No authors listed. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan;251(3):365-74.
24. Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res. 2010;42:23-30.
25. Zieve FJ, Kalin MF, Schwartz S, Jones MR, Bailey WL. Results of the Glucose-Lowering Effect of Welchol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83.

26. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes (abstract). Endocr Pract. 2010 Jul-Aug;16(4):629-40.
27. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med. 2008;168(18):1975-83.
28. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-84.
29. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531-40.
30. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycosylated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009;7(3):255-8.
31. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy (abstract). Endocr Pract. 2010 Jan-Feb;16(1):53-63.
32. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009361.
33. Institute for Clinical Systems Improvement (ISCI). Healthcare guideline: lipid management in adults 12th ed., 2011 [guideline on the Internet]. ICSI. 2011 [cited 2013 Jul 22]. Available from: http://www.icsi.org/lipid_management_3/lipid_management_in_adults_4.html.
34. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr;19(2):327-36.
35. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013 Jan;36 Suppl 1:S11-66.

Therapeutic Class Review
Bile Acid Sequestrants

Overview/Summary

There are several classes of medications used to alter lipids including the hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), fibric acid derivatives, bile acid sequestrants and nicotinic acid (niacin). Each medication class differs with respect to the mechanism by which they alter lipids, as well as to what degree; therefore, Food and Drug Administration (FDA)-approved indications for a particular medication class are influenced by the underlying lipid abnormality.

Cholesterol is a fat-like substance (lipid) that is present in cell membranes and is a precursor of bile acids as well as steroid hormones.[1] The bile acid sequestrants bind bile acids in the intestine through anion exchange, which causes an interruption of their reabsorption. This reduction leads to feedback regulation to increase the conversion of cholesterol to bile acids. The major action of these agents is to reduce low density lipoprotein cholesterol (LDL-C). Furthermore, the overall reduction in cholesterol causes intrahepatic cholesterol to be reduced which in turn enhances LDL receptor expression. Receptors then bind LDL from the plasma causing a further reduction in blood cholesterol.[1,2] Bile acid sequestrants cause a minimal increase in high density lipoprotein cholesterol through a different mechanism.[2]

Use of bile acid sequestrants is effective in patients with mild to moderate elevations of LDL-C.[1,2] When administered as monotherapy, these agents may reduce LDL-C by 10 to 24%, depending on the dose administered.[2] Bile acid sequestrants are also effective as add on therapy in patients with markedly elevated LDL-C who are already receiving a statin or niacin.[1,2] In this instance, doubling the dose of the statin has the potential to further reduce LDL-C by six percent, while adding a moderate dose of a bile acid sequestrant to a statin can potentially produce a 12 to 16% further reduction in LDL-C. Of note, these agents tend to increase triglyceride (TG) levels; therefore, they are contraindicated as monotherapy in patients with high TG levels and in familial dysbetalipoproteinemia.[1]

There are three bile acid sequestrants available: cholestyramine (Prevalite®, Questran®, Questran Light®), colesevelam (Welchol®) and colestipol (Colestid®, Flavored Colestid®). Cholestyramine and colestipol are both available as powders to be mixed with water or juice, and are typically administered once or twice daily with meals.[3-5] Colestipol is also available as a tablet (Colestid®), and the powder formulation is available in two flavors: tasteless (Colestid®) and orange flavored (Flavored Colestid®).[5,6] Colesevelam is available as a powder and as a tablet, and is also typically administered once or twice daily.[7] Colesevelam is more potent compared to either cholestyramine or colestipol.[1] In addition, colesevelam may be more easily administered and better tolerated than other agents.[1,2] All bile acid sequestrants are available generically, with the exception of colesevelam (Welchol®).

In general, all of the agents are FDA-approved for adjunct treatment in patients with hypercholesterolemia.[3-7] Cholestyramine is also FDA-approved for relief of pruritus associated with partial biliary obstruction.[3,4] Colesevelam also has additional FDA-approved indications for use as monotherapy in children 10 to 17 years of age for the treatment of heterozygous familial hypercholesterolemia, and as adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes.[7]

In general, therapeutic lifestyle changes, including diet, exercise and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia.[1,8,9] When LDL lowering is required, initial treatment with a statin, a bile acid sequestrant or niacin is recommended.[1] In general, the statins are considered first-line therapy for decreasing LDL-C levels.[1,8-10] If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or niacin should be considered.[1] Statins are also considered first-line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy.[8] In addition, the bile acid sequestrants are recognized as the therapy of choice for the management of pruritus associated with primary biliary cirrhosis.[11]

In the management of patients with diabetes, the American Association of Clinical Endocrinologists note that colesevelam may provide a possible benefit or few adverse events when given as part of dual or triple therapy in addition to metformin in patients with a glycosylated hemoglobin of ≥7.5%.[12] In general, the American Diabetes Association recommends that a statin be added to lifestyle therapy, regardless of baseline lipid levels, in patients with diabetes. If maximally tolerated doses of statins fail to significantly lower LDL-C (<30% reduction from baseline), no strong evidence exists that combination therapy should be used. Niacin, fenofibrate, ezetimibe, and bile acid sequestrants offer additional LDL-C lowering compared to statins alone; however, there is no evidence that combination therapy provides a significant cardiovascular disease risk reduction over statin therapy alone.[13]

Medications

Table 1. Medications Included Within Class Review

Generic Name (Trade name)	Medication Class	Generic Availability
Cholestyramine (Prevalite®*, Questran®*, Questran Light®*)	Bile acid sequestrants	✔
Colesevelam (Welchol®)	Bile acid sequestrants	-
Colestipol (Colestid®*, Flavored Colestid®*)	Bile acid sequestrants	✔

*Generic available in at least one dosage form and/or strength.

Indications

Table 2. Food and Drug Administration (FDA)-Approved Indications[3-7]

Indication	Cholestyramine	Colesevelam	Colestipol
Adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia who do not respond adequately to diet*	✔		✔ †
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes		✔	
Adjunct to diet and exercise to reduce elevated low density lipoprotein cholesterol levels in adults with primary hyperlipidemia as monotherapy or in combination with a statin		✔	
Monotherapy or in combination with a statin to reduce low density lipoprotein cholesterol levels in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia‡		✔	
Relief of pruritus associated with partial biliary obstruction§	✔		

*May be useful to lower low density lipoprotein cholesterol (LDL-C) levels in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
†For the reduction of elevated serum total cholesterol and LDL-C.
‡If after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present in the pediatric patient.
§Has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit elevated cholesterol as part of their disease.

In addition to their Food and Drug Administration-approved indications, the bile acid sequestrants have the potential to be used off-label in several different clinical situations. Cholestyramine has the potential of being used off-label for the treatment of bile acid malabsorption syndrome, heterozygous familial hypercholesterolemia and generalized atherosclerosis. Colesevelam and colestipol have the potential to be used off-label for the treatment of familial hypercholesterolemia, while colestipol may also be used off-label for the treatment of generalized atherosclerosis.[14]

Pharmacokinetics

Table 3. Pharmacokinetics[3-7]

Generic Name	Bioavailability (%)	Renal Elimination (%)	Active Metabolites	Half-Life (hours)
Cholestyramine	Not reported	Not reported	Not reported	Not reported
Colesevelam	0	0.05	Not reported	Not reported
Colestipol	0	0.05	Not reported	Not reported

Clinical Trials

Clinical trials demonstrating the safety and efficacy of the bile acid sequestrants in their Food and Drug Administration approved indications are outlined in Table 4.[15-41] In general, the bile acid sequestrants consistently demonstrated "superiority" over placebo in the management of hyperlidpidemia.[16-25] In line with current clinical guidelines, results also demonstrated that the addition of a bile acid sequestrant to another lipid lowering agent has the potential to produce further reductions in low density lipoprotein cholesterol levels compared to monotherapy with either of the agents.[20-27]

The Lipid Research Clinical Coronary Primary Prevention trial demonstrated that compared to placebo, treatment with cholestyramine reduced the risk of coronary heart disease death and/or nonfatal myocardial infarction in asymptomatic males with primary hypercholesterolemia (P<0.05).[28,29]

Several clinical trials have demonstrated the safety and efficacy of colesevelam as adjunct therapy in adults with type 2 diabetes. In all of the trials, patients were receiving background therapy with established oral antidiabetic agents.[30-40] Compared to placebo, the addition of colesevelam resulted in significant reductions in glycosylated hemoglobin (HbA_{1c}) levels.[31-39] In one trial colesevelam or placebo were added to metformin therapy for 16 weeks. Treatment with metformin plus colesevelam resulted in a significant reduction in Hb_{A1c} after 16 weeks compared to patients receiving metformin plus placebo (mean treatment difference: -0.3%; P=0.0035). Combination therapy with metformin plus colesevelam significantly reduced low density lipoprotein cholesterol (LDL-C) (-16.3%), total cholesterol (-6.1%) and non-high density lipoprotein cholesterol (non–HDL-C) (-8.3%) compared to patients receiving metformin plus placebo (P<0.001 for all).[39] A trial comparing add-on therapy with either colesevelam, rosiglitazone or sitagliptin in type 2 diabetics inadequately controlled on a stable metformin regimen demonstrated that least squares mean reductions in HbA_{1c} levels from baseline for each treatment were comparable (-0.3 [P<0.031], -0.6 [P<0.001] and -0.4% [P<0.008]). In this trial, after 16 weeks of treatment, 17.9, 35.2 and 27.3% of patients receiving colesevelam, rosiglitazone and sitagliptin achieved a HbA_{1c} <7.0% (P values not reported).[40]

In a Cochrane Review of six randomized controlled trials of patients 18 years of age and older with type 2 diabetes and an elevated LDL-C the addition of colesevelam to other hypoglycemic agents significantly reduced HbA_{1c} compared to placebo (mean difference, -0.5%; 95% confidence interval (CI), -0.6 to -0.4; P<0.00001). In addition, colesevelam with add-on hypoglycemic agents demonstrated a significant reduction in fasting plasma glucose compared to placebo (mean difference, -15 mg/dL; 95% CI, -22 to -8; P<0.0001).[41]

Table 4. Clinical Trials

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Hypercholesterolemia				
Davidson et al[15] Colesevelam 0.75 g BID, titrated up to a maximum of 1.875 g BID If a 15 to 30% LDL-C reduction was not achieved with the maximum colesevelam dose by week 12, low dose statin or niacin therapy could be added.	ES, OL Patients ≥18 years of age with primary hyper-cholesterolemia (LDL-C ≥160 mg/dL and TG ≤300 mg/dL)	N=260 50 weeks	Primary: Mean change from baseline in LDL-C Secondary: Mean percent change from baseline in LDL-C; mean change and mean percent change from baseline in TC, TG and HDL-C; safety	Primary: Colesevelam monotherapy or combination therapy resulted in significant mean LDL-C level reduction of 29.6 mg/dL (from 185.8 to 156.2 mg/dL), corresponding to a 15.0% reduction from baseline (*P*<0.00 for both). Secondary: Colesevelam reduced the mean TC level from baseline to week 50 (270.2 to 258.3 mg/dL) by 11.9 mg/dL (4.0%; *P*<0.001). The median TG level increased from baseline to week 50 (145.5 to 165.0 mg/dL) by 13.0 mg/dL (10.3%). The median HDL-C level increased from baseline to week 50 (49.5 to 54.0 mg/dL) by 5.0 mg/dL (10.8%; *P*<0.001). Twenty three patients discontinued colesevelam due to treatment-emergent adverse events. Treatment-emergent adverse events were reported by 225 patients (86.5%), with the majority of adverse events (74.7%) classified as mild to moderate in severity. The most common adverse events included infection (28.5%), constipation (16.5%), flatulence (13.5%) and general pain (13.1%).
Stein et al[16] Colesevelam vs placebo Period 1 (week -4 to day 0): diet and placebo run in period. Period 2 (day 1 to week 8): DB treatment of colesevelam 1.875 or 3.75 g/day vs placebo.	DB, MC, PC, PG, RCT Patients 10 to 17 years of age with a diagnosis of heterozygous familial hyper-cholesterolemia with a LDL-C >160 mg/dL on a stable NCEP diet for ≥4 weeks and naïve to lipid lowering therapy or LDL-C >130 mg/dL on a	N=194 32 weeks	Primary: Percent change from baseline to week eight in LDL-C Secondary: Percent change in LDL-C from week eight to week 26 and from baseline to week 26; percent change in TC, non-HDL-C, TG, HDL-C, apo A-I and apo B	Primary: Colesevelam 3.75 and 1.875 g/day resulted in a significant mean treatment difference in LDL-C of -12.5 (*P*<0.001) and -6.3% (*P*=0.031), respectively, compared to placebo at week eight. Secondary: During OL treatment of colesevelam, the mean change in LDL-C was -9.3% (*P*<0.001) from week eight to 26. Patients who received placebo during the DB period had the greatest change in mean LDL-C (-14.5%; *P*<0.001), followed by patients receiving colesevelam 1.875 g/day (-11.6%; *P*<0.001) and 3.75 g/day (-1.9%; *P*=0.482). Treatment with colesevelam 3.75 g/day also resulted in a significant mean treatment difference in TC (-7.4%; *P*=0.001), non-HDL-C (-10.9%; *P*=0.0001), apo B (-8.3%; *P*=0.0009), HDL-C (6.1%; *P*=0.008) and apo A-I (6.9%; *P*=0.006) at week eight. There was a nonsignificant median increase

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Period 3 (week 8 to week 26): OL safety evaluation of colesevelam 3.75 g/day.	stable NCEP diet for ≥6 weeks plus a statin and ≥1 of the following: history/presence in patients/first-degree relative of tendinous xanthoma or premature corneal arcus; first-degree adult relative/ biologic offspring with a mutation in the LDL receptor or apo B gene; the presence of untreated LDL-C >190 mg/dL in a first-degree adult relative or the presence of LDL-C >160 mg/dL in siblings <18 years of age and/or a first-degree relative with premature CAD or sudden death from natural causes before 55 (males) or 60 years of age (females)		from baseline to week eight, week eight to week 26 and from baseline to week 26; percentage of patients achieving LDL-C <110 mg/dL	in TG (5.1%; *P*=0.466) at week eight compared to placebo. Over the entire treatment period, treatment with colesevelam 3.75 g/day resulted in a mean reduction from baseline in LDL-C of -14.0% (*P*<0.001) across all patients. Colesevelam 3.75 g/day also achieved clinically significant mean reductions from baseline in TC (-8.0%; *P*<0.001), non-HDL-C (-11.3%; *P*<0.001) and apo B (-11.3%; *P*<0.001); clinically significant increases from baseline in mean HDL-C (8.1%; *P*<0.001) and apo A-I (5.6%; *P*<0.001) and a significant median increase in TG (11.5%; *P*<0.001). Seven patients (3.7%) achieved the goal of LDL-C <110 mg/dL during period two; five were receiving colesevelam 3.75 g/day and two were receiving colesevelam 1.875 g/day. Of the seven patients, two were statin naïve and five were taking a statin.
Rosenson et al[17] Colesevelam 1.5 to 3.75 g/day	DB, MC, PC, RCT Adults with hyper-cholesterolemia (LDL-C >160 mg/dL)	N=137 6 weeks	Primary: LDL particle size and number Secondary:	Primary: Mean LDL particle size increased significantly with colesevelam 3.75 g/day compared to placebo (*P*=0.01). Mean LDL particle number decreased significantly by 13.7% with

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs placebo			Not reported	colesevelam 3.75 g/day compared to placebo (*P*=0.0002). Mean LDL particle number decreased significantly by 6.8% with colesevelam 3.0 g/day compared to placebo (*P*=0.03). Secondary: Not reported
Bays et al[18] Colesevelam 3.75 g/day vs placebo	MA of 3 DB, MC, PC, PG, RCTs Patients ≥18 years of age with a LDL-C 100 to 250 mg/dL, TG ≤300 mg/dL and on stable doses of statin therapy (atorvastatin, pravastatin or simvastatin) for ≥4 weeks	N=204 6 weeks	Primary: Mean percent change from baseline in LDL-C Secondary: hsCRP; absolute and percent change in HDL-C, TC, apo A-I, apo B and TG; absolute change in hsCRP; safety	Primary: Colesevelam achieved significantly greater reductions in LDL-C compared to placebo (*P*<0.01 for absolute difference; *P*≤0.001 for percent treatment difference). Secondary: The hsCRP levels decreased significantly compared to placebo when colesevelam was combined with simvastatin or pravastatin (*P*=0.0154 and *P*=0.0279, respectively). Colesevelam treatment did not significantly increase HDL-C compared to placebo (*P*>0.05). Colesevelam treatment was associated with significantly greater reductions in TC compared to placebo (*P*<0.05). Apo B concentrations were not significantly different between treatment groups (*P* value not reported). No serious drug-related adverse events were reported. The incidence of drug-related adverse events was higher with colesevelam (13 to 26%) compared to placebo (0 to 13%; *P* value not reported).
Insull et al[19] Colesevelam 2.3 to 4.5 g/day vs	DB, MC, PC, RCT Patients with primary hyper-cholesterolemia (LDL-C 130 to 220 mg/dL)	N=467 32 weeks (8 weeks of diet lead in plus 24 weeks of DB	Primary: Mean absolute change from baseline in LDL-C Secondary: Mean percent	Primary: All doses of colesevelam resulted in significant absolute and percent change decreases in LDL-C at the end point as compared to placebo (*P*<0.001 for all). Absolute change and percent decreases in LDL-C for the 2.3, 3.0, 3.8 and 4.5 g doses were 14 (9%), 19 (12%), 24 (15%) and 28 mg/dL (18%) (*P* values not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
placebo		treatment)	change in LDL-C; mean absolute and percent change in TC, apo B and apo A-I; median absolute change and percent change in HDL-C and TG	Secondary: All doses of colesevelam resulted in significant reductions of TC compared to placebo (*P*<0.001). Absolute change and percent decreases in TC for the 2.3, 3.0, 3.8 and 4.5 g doses were 10 (4%), 15 (6%), 18 (7%) and 24 mg/dL (10%; *P* values not reported). All doses of colesevelam resulted in significant increases in HDL-C compared to placebo (*P*<0.001). Absolute change and percent increases in HDL-C for the 2.3, 3.0, 3.8 and 4.5 g doses were 2 (3%), 2 (4%), 2 (3%) and 2 mg/dL (3%; *P* values not reported). All doses of colesevelam resulted in significant reductions in apo B relative to baseline (*P*<0.001). Changes in apo A-I did not result in significant changes relative to baseline, except the 2.3 and 3.0 g doses resulted in significant changes in apo A-I (*P*=0.02 and 0.03, respectively) TG levels did not change significantly as compared to placebo; however, increases of 5 to 10% were observed within groups from baseline to end point (*P*<0.05).
Huijgen et al[20] Colesevelam 3,750 mg/day vs placebo All patients were receiving ezetimibe/simvastatin.	DB, PC, RCT Patients 18 to 75 years of age with familial hyper-cholesterolemia refractory to treatment	N=86 12 weeks	Primary: Percent change from baseline to week six in LDL-C Secondary: Percentage change from weeks six to 12 in HDL-C, TC, TG, apo A1, apo B, apo B/A1; percentage change from baseline to week	Primary: The between-group difference in change from baseline LDL-C was significant at week six, with an LSM change of -18.5% (95% CI, -25.3 to -11.8) Secondary: Between group differences (95% CI) in LDL-C, TC, HDL-C, TG and apo B/A1 after 12 weeks were -12.0 (-17.8 to -6.3), -7.3 (-12.0 to -2.6), 3.3 (-2.4 to 9.0), 2.8 (-10.4 to 15.9) and -12.2% (-20.2 to -4.2). Mean TC concentrations were significantly reduced with colesevelam compared to placebo at weeks six and 12 (LSM between-group differences, -11.1 and -7.3%; *P*<0.001 and *P*<0.003). On average, TG levels increased with colesevelam from baseline to weeks six and 12. There was no significant group differences in HDL-C at week six and 12 (*P* values not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			12 in LDL-C; proportion of patients achieving an LDL-C target of ≤2.5 mmol/L at weeks six and 12; proportion of patients with a decrease from baseline in LDL-C ≥15% at weeks six and 12; absolute changes in fasting glucose, HbA_{1c}, and hsCRP at weeks six and 12	The difference in the proportions of patients who achieved the target LDL-C (≤2.5 mmol/L) with colesevelam and placebo was not significant (9 vs 3%; *P* value not reported). The proportion of patients who achieved ≥15% reduction in LDL-C at week six was significantly higher with colesevelam (32 vs 0%; *P*<0.001). This difference remained significant at week 12 (30 vs 8%; *P*=0.012). Although not significant at week six (-0.06%), the LSM between-group difference in change from baseline to week 12 in mean HbA_{1c} concentration was significant (-0.12%; *P*=0.027). There were no significant between-group differences in fasting glucose or hsCRP at week six and 12.
Blankernhorn et al[21] Colestipol 30 g/day plus niacin 3 to 12 g/day vs placebo	DB, PC, RCT Nonsmoking men 49 to 59 years of age with progressive atherosclerosis who had coronary bypass surgery not involving valve replacement performed ≥3 months prior and a fasting blood cholesterol level 185 to 350 mg/dL	N=188 2 years	Primary: Coronary global change score Secondary: Change from baseline in lipid parameters	Primary: Deterioration in overall coronary status was significantly less with combination therapy compared to placebo (*P*<0.001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2 and 2.4% of patients receiving combination therapy and placebo (*P*=0.002). Combination therapy resulted in a significant reduction in the average number of lesions per patient that progressed (*P*<0.03) and the percentage of patients with new atheroma formation in native coronary arteries (*P*<0.03). The percentage of patients receiving combination therapy with new lesions (*P*<0.04) or any adverse change in bypass grafts (*P*<0.03) was significant reduced. Secondary: Large, significant decreases in TC (26 vs 4%), TG (22 vs 5%), LDL-C (43 vs 5%) and LDL-C/HDL-C (57 vs 6%), and a large, significant increase in HDL-C (37 vs 2%) were achieved with combination therapy compared to

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				placebo (*P*<0.001 for all). Modifications in lipid parameters achieved with combination therapy were significant compared to baseline values (*P* values not reported).
Brown et al[22] Colestipol 5 to 10 g TID plus niacin 125 mg BID, titrated to 1 to 1.5 g TID vs colestipol 5 to 10 g TID plus lovastatin 20 mg BID, titrated to 40 mg BID vs placebo (or colestipol if LDL-C was elevated)	DB, PC, RCT Men ≤62 years of age with elevated apo B and a family history of CAD	N=120 32 months	Primary: Average change in the percent stenosis for the worst lesion in each of the nine proximal segments Secondary: Average changes in all lesions measured in each patient and in proximal lesions causing ≥50% (severe) stenosis or <50% (mild) stenosis at baseline	Primary: On average, placebo (conventional therapy) increased the index of stenosis by 2.1 percentage points from a baseline of 34%. By contrast, it decreased by 0.7 percentage points with colestipol plus lovastatin and by 0.9 percentage points with colestipol and niacin (*P*<0.003 for trend). At trial end, on average, these nine lesions were almost three percentage points less severe among patients treated intensively compared to conventionally. This difference represents almost one-tenth of the amount of disease present at baseline (34% stenosis). Secondary: Placebo (conventional therapy) resulted in consistent worsening of disease when looking at the effect of treatment on certain subsets of lesions (all lesions measured in each patient, lesions causing severe or mild stenosis and those that did not cause total occlusion at baseline). The results with both treatment groups were significantly different from those receiving conventional therapy for each subset, demonstrating either a mean regression or no change in severity of disease.
Hunninghake et al[23] Colesevelam 3.8 g/day vs atorvastatin 10 mg/day vs colesevelam 3.8 g/day plus atorvastatin 10 mg/day	DB, MC, PC, RCT Patients with LDL-C ≥160 mg/dL and TG ≤300 mg/dL	N=91 4 weeks	Primary: Change from baseline in LDL-C Secondary: Change from baseline in TC, HDL-C, TG, apo B, apo A-I and lipoprotein	Primary: All treatments resulted in significant LDL-C reductions as compared to baseline. LDL-C reductions from baseline were -12% with colesevelam (*P*<0.05), -38% with atorvastatin 10 mg (*P*<0.0001), -48% with colesevelam plus atorvastatin (*P*<0.0001) and -53% with atorvastatin 80 mg (*P*<0.0001), respectively. Secondary: Colesevelam reduced TC by 6% (*P*<0.05), increased HDL-C by 3% (*P*<0.05) and increased TG by 10% (*P* value not reported). Atorvastatin 10 mg reduced TC by 27% (*P*<0.0001), increased HDL-C by 8% (*P*<0.05) and reduced TG by 24% (*P*<0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs atorvastatin 80 mg/day vs placebo				Colesevelam plus atorvastatin reduced TC by 31% (*P*<0.0001), increased HDL-C by 11% (*P*<0.05) and reduced TG by 1% (*P* value not reported). Atorvastatin 80 mg reduced TC by 39% (*P*<0.0001), increased HDL-C by 5% (*P*<0.05) and reduced TG by 33% (*P*<0.0001). Reductions in TC were significant between all treatment groups except atorvastatin 10 mg relative to colesevelam plus atorvastatin. No significant differences in HDL-C were found between the treatment groups (*P* values not reported). Apo B levels decreased significantly for with all treatments relative to baseline (*P*<0.01). No significant changes in apo A-I and lipoprotein were reported (*P* values not reported).
Davidson et al (abstract)[24] Colesevelam 2.3 g/day vs lovastatin 10 mg/day vs colesevelam 2.3 g/day plus lovastatin 10 mg/day administered together vs colesevelam 2.3 g/day plus lovastatin 10 mg/day administered apart vs placebo	DB, MC, PC, RCT Patients with an elevated LDL-C level	N=135 4 week	Primary: Percent change from baseline in LDL-C Secondary: Changes in TC, HDL-C, TG and apo B	Primary: Colesevelam plus lovastatin administered together significantly reduced LDL-C by 34% compared to placebo (-60 mg/dL; *P*<0.0001). Colesevelam plus lovastatin administered apart significantly reduced LDL-C by 32% compared to placebo (-53 mg/dL; *P*<0.0001). Lovastatin reduced LDL-C by 22% compared to placebo (-39 mg/dL; *P* value not reported). Colesevelam reduced LDL-C by 7% compared to placebo (-13 mg/dL; *P* value not reported). Colesevelam plus lovastatin administered together or apart were more effective than either treatment alone (*P*<0.05). Secondary: Colesevelam plus lovastatin administered together or apart resulted in significant reductions in TC by 21% and apo B by 24% from baseline (*P*<0.0001 for each). No significant effect on HDL-C or TG was observed for either of the combination treatments (*P* value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Knapp et al[25] Colesevelam 3.8 g/day vs simvastatin 10 mg/day vs colesevelam 3.8 g/day plus simvastatin 10 mg/day vs colesevelam 2.3 g/day vs simvastatin 20 mg/day vs colesevelam 2.3 g/day plus simvastatin 20 mg/day vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with LDL-C ≥160 mg/dL and TG ≤300 mg/dL who are not taking cholesterol lowering medication	N=258 6 weeks	Primary: Change from baseline in LDL-C Secondary: Percent change in LDL-C; mean and percent change from baseline in TC, HDL-C, TG, apo B and apo A-I	Primary: LDL-C changes from baseline were -7 mg/dL with placebo (P<0.05), -31 mg/dL with colesevelam 3.8 g (P<0.0001), -48 mg/dL with simvastatin 10 mg (P<0.0001), -80 mg/dL with colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), -17 mg/dL with colesevelam 2.3 g (P<0.0001), -61 mg/dL with simvastatin 20 mg (P<0.0001) and -80 mg/dL with colesevelam 2.3 g plus simvastatin 20 mg (P<0.0001), respectively. Secondary: LDL-C percent changes from baseline were -4% with placebo (P<0.05), -16% with colesevelam 3.8 g (P<0.0001), -26% with simvastatin 10 mg (P<0.0001), -42% with colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), -8% with colesevelam 2.3 g (P<0.0001), -34% with simvastatin 20 mg (P<0.0001) and -42% with colesevelam 2.3 g plus simvastatin 20 mg (P<0.0001), respectively. Significant changes from baseline were observed for all treatments in mean and percent change in TC (P<0.0001 for all, except colesevelam 2.3 g; P<0.05). Significant changes from baseline were observed for mean and percent change in HDL-C with simvastatin 10 mg (P<0.05), colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), colesevelam 2.3 g (P<0.05), simvastatin 20 mg (P<0.05) and colesevelam 2.3 g plus simvastatin 20 mg (P<0.05). Significant changes from baseline were observed for mean and percent change in TG with colesevelam 3.8 g (P<0.05), simvastatin 10 mg (P<0.05), simvastatin 20 mg (P<0.05) and colesevelam 2.3 g plus simvastatin 20 mg (P<0.05). Significant reductions from baseline for apo B were observed with all treatments. Reductions were significant (P<0.05) compared to placebo for all treatments except colesevelam 2.3 g (P value not reported). Significant increases in apo A-I were achieved with all treatments except simvastatin 10 mg (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Eriksson et al[26] Cholestyramine 16 g/day vs cholestyramine 8 g/day plus pravastatin 20 mg/day vs pravastatin 20 mg/day vs pravastatin 40 mg/day	MC, RCT Patients 30 to 65 years of age	N=2,036 12 months	Primary: Percent change from baseline in LDL-C Secondary: Compliance	Primary: Percent changes in LDL-C from baseline to end point with cholestyramine, cholestyramine plus pravastatin, pravastatin 20 mg and pravastatin 40 mg were -26 (95% CI, -23 to -29), -36 (95% CI, -33 to -39), -27 (95% CI, -25 to -29) and -32% (95% CI, -30 to -34), respectively. Secondary: Compliance rates with cholestyramine, cholestyramine plus pravastatin, pravastatin 20 mg and pravastatin 40 mg were 44, 53, 76 and 78%, respectively (*P* values not reported). Pravastatin adverse events were the most common reasons for withdrawal. Adverse events were most common with cholestyramine and cholestyramine plus pravastatin.
Ballantyne et al[27] Rosuvastatin 80 mg/day vs rosuvastatin 80 mg/day plus cholestyramine 16 g/day All patients received rosuvastatin 40 mg/day for a 6-week run in period.	MC, OL, PG, RCT Patients ≥18 years of age with severe hyper-cholesterolemia (LDL-C 190 to 400 mg/dL) and fasting TG <400 mg/dL	N=147 12 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent change from baseline in LDL-C after six weeks of 40 mg rosuvastatin; percent change from baseline at six and 12 weeks of rosuvastatin treatment for TC, HDL-C, TG, apo A-I, apo B, lipid ratios (LDL:HDL) and inflammatory	Primary: At 12 weeks, no significant difference between the treatment groups was observed. Rosuvastatin achieved a LDL-C reduction of 56.4% and rosuvastatin plus cholestyramine achieved a reduction of 60.5% (*P*<0.08). Secondary: The LDL-C reductions were 52.2% after treatment with rosuvastatin 40 mg. Changes in TC (*P*=0.20), HDL-C (*P*=0.71), TG (*P*=0.47), apo B (*P*=0.75), apo A-I (*P*=0.53) and lipid ratios (*P*=0.17) were not significantly different between the treatment groups. Decreases in CRP were 29% after six weeks of treatment, 42% with rosuvastatin 80 mg and 48% with rosuvastatin 80 mg plus cholestyramine (*P* value not reported). Forty nine percent of patients receiving cholestyramine were not compliant with the treatment.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			markers (CRP, IL6); compliance	
Hypercholesterolemia Clinical Outcomes Trials				
No authors listed[28,29] The Lipid Research Clinics Coronary Primary Prevention Trial Cholestyramine vs placebo	DB, MC, RCT Asymptomatic males with primary hyper-cholesterolemia following a moderate cholesterol lowering diet	N=3,806 7.4 years (average)	Primary: CHD death and/or nonfatal MI Secondary: Changes in TC and LDL-C; incidence rates of positive stress tests, angina and coronary bypass surgery	Primary: Cholestyramine was associated with a 19% reduction in risk of CHD death or nonfatal MI (P<0.05). Secondary: Cholestyramine achieved reductions in TC and LDL-C of 13.4 and 20.3% compared to 4.9 and 7.7% with placebo (P values not reported). Incidence rates of positive stress tests, angina and coronary bypass surgery were decreased with cholestyramine by 25, 20 and 21%, respectively (P values not reported).
Type 2 Diabetes				
Goldfine et al[30] Colesevelam 3.75 g/day	ES, OL Patients who completed 1 of 3 DB RCTs wherein colesevelam was added to insulin-, metformin- and sulfonylurea-based therapies	N=509 52 weeks	Primary: Safety and tolerability Secondary: Change from baseline in HbA_{1c} and FPG, percent change in lipid and lipoprotein levels, change in lipid ratios, percentage of patients who achieved HbA_{1c} <7% at week 52	Primary: In total, 361 patients (70.9%) experienced an adverse event during the ES phase. The majority of adverse events (88.1%) were mild to moderate in severity. Fifty six patients (11.0%) experienced a drug-related adverse event that was gastrointestinal in nature. In general, the incidence of drug-related adverse events was greater in patients who received placebo in the DB phase relative to those who had received colesevelam. Thirty five patients (6.9%) discontinued due to an adverse event. Sixteen patients (3.1%) discontinued due to a drug-related adverse event. Fifty four patients (10.6%) had a serious adverse event; only one serious adverse event was considered by the investigator to be drug-related. Twelve patients (2.4%) discontinued treatment due to a serious adverse event. Two patients died during the trial (MI and pulmonary embolism); both events were considered by the investigator to be unrelated to colesevelam. Secondary: An overall reduction in mean HbA_{1c} was maintained in patients who received colesevelam during the DB phase and continued on this treatment during the OL, ES phase. After 68 to 78 total weeks of colesevelam treatment there was an overall reduction in HbA_{1c} of 0.3% from baseline.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				In general, findings for FPG were consistent with observed effects on HbA_{1c}. Improvements in mean LDL-C levels achieved with colesevelam during the DB phases were maintained, and in both the patients who received colesevelam for 68 to 78 weeks and those that received colesevelam for 52 weeks, effects were sustained over the 52 week ES phase. At week 52, lipid and lipoprotein levels were similar between the group that received colesevelam for the entire treatment period and those who originally received placebo. At week 52, 72 patients (14.1%) achieved an HbA_{1c} <7% and 137 patients (26.9%) achieved a reduction in HbA_{1c} of ≥0.7% from baseline. Similarly, 126 patients (24.8%) achieved a reduction in FPG ≥30 mg/dL from baseline at week 52.
Zieve et al[31] GLOWS Colesevelam 3.75 g/day vs placebo	DB, PC, PG, PRO, RCT Patients with type 2 diabetes, an HbA_{1c} 7 to 10% and on a stable dose of a sulfonylurea and/or metformin as their only antidiabetic agent for ≥90 days	N=65 12 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Changes in fructosamine, FPG, postprandial glucose and meal glucose response (difference between pre and postprandial glucose levels); percent change in lipids (LDL-C, TC, TG, apo A-I and apo B)	Primary: The change from baseline in HbA_{1c} with colesevelam and placebo was -0.3 and 0.2%, respectively (*P*=0.007). For patients with a baseline HbA_{1c} ≥8 at baseline, there was a greater difference in HbA_{1c} (-1%) after 12 weeks of treatment (*P*=0.002). The reduction in HbA_{1c} in the treatment groups did not differ based on oral antidiabetic treatment (*P* value not reported). Secondary: Significantly lower fructosamine levels were observed with colesevelam at week 12 (*P*=0.011). Significantly lower FPG levels were observed with colesevelam at weeks four (*P*=0.016) and eight (*P*=0.011), but not at week 12 (*P* value not reported). Significantly lower postprandial glucose levels were observed with colesevelam at week 12 (*P*=0.026). No significant difference between the treatment groups was observed in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				meal glucose response (*P*=0.195). Significantly lower lipid parameters, including LDL-C (*P*=0.007), TC (*P*=0.019), apo B (*P*=0.019) and LDL particle concentration (*P*=0.003) were observed with colesevelam compared to placebo, respectively.
Rosenstock et al (abstract)[32] Colesevelam 3.75 g/day vs placebo All patients received OL metformin 850 mg/day, titrated at week 2 to 1,700 mg/day.	DB, PC, RCT Adult patients with type 2 diabetes (HbA_{1c} 6.5 to 10.0%) and hyper-cholesterolemia (LDL-C ≥100 mg/dL)	N=286 16 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Change from baseline in LDL-C, TC, non-HDL-C, apo B, hsCRP, apo A-1 and TG; proportion of patients who achieved recommended treatment goals; safety and tolerability	Primary: Mean HbA_{1c} was reduced by 1.1 and 0.8% with colesevelam (from 7.8% at baseline to 6.6% at trial end) and placebo (from 7.5 to 6.7% at trial end), resulting in a treatment difference of -0.3% at trial end (*P*=0.0035). Secondary: Colesevelam significantly reduced LDL-C (-16.3%), TC (-6.1%), non-HDL-C (-8.3%), apo B (-8.0%) and hsCRP (-17%) (*P*<0.01 for all). Colesevelam significantly increased apo A-1 (4.4%) and TG (18.6%) compared to placebo (*P*<0.01 for all). The proportion of patients who achieved recommended goals with colesevelam compared to placebo, respectively, were as follows: HbA_{1c} <7; 67 vs 56% (*P*=0.0092), LDL-C <100 mg/dL; 48 vs 18% (*P*<0.001) and composite HbA_{1c} <7% plus LDL-C <100 mg/dL; 40 vs 12 (*P*<0.001). Safety and tolerability were similar between the two treatment groups.
Bays et al[33] Colesevelam 3.75 g/day vs placebo All patients continued their current antidiabetic treatment regimens. All patients entered a 2 week, SB, placebo run in	DB, MC, PC, PG, RCT Patients 18 to 75 years of age with type 2 diabetes with inadequate glycemic control (HbA_{1c} 7.5 to 9.5%), taking a stable dose (≥90 days) of metformin monotherapy or metformin in combination with	N=316 26 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Mean change in HbA_{1c}, FPG and fructosamine levels from baseline to weeks six, 12, 18 and 26 for metformin monotherapy or combination	Primary: Colesevelam reduced LSM HbA_{1c} level by -0.39% compared to 0.15% with placebo, resulting in a significant LSM treatment difference of -0.54% (*P*<0.001). A significant LSM treatment difference was observed beginning at week six (-0.46%; *P*<0.001). Secondary: Mean reductions in HbA_{1c} level when colesevelam was added to either metformin monotherapy or combination therapy were consistent with findings for the total population at week 26 (metformin monotherapy, -0.44 vs 0.02%; LSM treatment difference, -0.47%; *P*=0.002 and metformin combination therapy, -0.35 vs 0.27%; LSM treatment difference, -0.62%; *P*<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
period.	other oral antidiabetic drugs		therapy; assessment of patients who experienced a predefined reduction in FPG level ≥30 mg/dL or in HbA_{1c} level ≥0.7% from baseline; mean change from baseline in C-peptide, adiponectin, insulin and HOMA index levels; mean change and mean percent change from baseline in TC, LDL-C, HDL-C, non-HDL-C, apo A-I and apo B; mean change from baseline in TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C and apo B/apo A-I; median change from baseline in hsCRP and TG	Colesevelam reduced FPG level compared to placebo at week 26 (-13.9 mg/dL; *P*=0.01), with a significant LSM treatment difference observed at week six (-20.8 mg/dL; *P*<0.001). Colesevelam reduced fructosamine level compared to placebo (-23.2 µmol/L; *P*<0.001), with a significant LSM treatment difference observed at week six (-25.5 µmol/L; *P*<0.001). In total, 71 (47.7%) and 54 (35.5%) patients receiving colesevelam and placebo experienced either a reduction in FPG level ≥30 mg/dL or in HbA_{1c} level ≥0.7% from baseline at week 26 (*P*=0.03). A significantly greater percentage of patients receiving colesevelam achieved an HbA_{1c} level reduction (38.3 vs 20.4%; *P*<0.001 vs placebo). Compared to placebo, colesevelam did not produce a significant LSM treatment difference for C-peptide level (-0.1 ng/mL; *P*=0.54). Similarly, no differences were observed in adiponectin (-0.3 µg/mL; *P*=0.52), insulin (-0.9 µIU/mL; *P*=0.51) or HOMA index (-0.3; *P*=0.68). Compared to placebo, colesevelam reduced LSM and mean percentage of LDL-C, TC, non-HDL-C and apo B levels at week 26 (*P*<0.001 for all). Compared to placebo, colesevelam was not associated with a significant LSM treatment difference in TG level (8.5 mg/dL; *P*=0.24). Compared to placebo, colesevelam reduced LSM TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C and apo B/apo A-I ratios at week 26 (*P*<0.003 for all). Compared to placebo, colesevelam resulted in a LSM treatment difference in hsCRP level of -0.40 mg/L (-14.4%; *P*=0.02).
Fonseca et al[34] Colesevelam 3.75 g/day vs	DB, MC, PC, PG, RCT Adult patients with type 2 diabetes who	N=461 26 weeks	Primary: Mean change from baseline in HbA_{1c}	Primary: Colesevelam reduced HbA_{1c} by 0.320±0.066% compared to an increase of 0.230±0.065% with placebo, resulting in a significant LSM treatment difference of -0.540±0.090% (*P*<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
placebo All patients continued their current antidiabetic treatment regimens. All patients entered a 2 week, SB, placebo run in period.	are inadequately controlled (HbA_{1c} 7.5 to 9.5%) on a stable dose of a sulfonylurea alone or in combination with additional antidiabetic agents for ≥90 days		Secondary: Mean change from baseline in FPG, fructosamine and C-peptide; mean change in HbA_{1c} for sulfonylurea monotherapy and combination therapy; percentage of patients achieving a reduction in FPG level ≥30 mg/dL or in HbA_{1c} level ≥0.7% from baseline; mean change in lipids, lipoproteins and lipid and lipoprotein ratios; median change and percent change in hsCRP and TG	Secondary: A significant LSM treatment difference between colesevelam and placebo in FPG was observed by week 26 (-13.50±5.14 mg/dL; *P*=0.009), with a significant treatment difference observed as early as six weeks (-13.70±3.98 mg/dL; *P*<0.001). Similar results were observed for changes with fructosamine levels (treatment difference, -21.40±4.59 µmol/L; *P*<0.001). No significant difference was observed in C-peptide levels (treatment difference, -0.170±0.101 ng/mL; *P*=0.102). Similar effects in the reduction of HbA_{1c} were observed in sulfonylurea monotherapy (-0.790±0.154%; *P*<0.001) and sulfonylurea combination therapy (-0.420±0.110%; *P*<0.001). A significantly greater percentage of patients receiving colesevelam achieved an HbA_{1c} reduction ≥0.7% compared to placebo (35.2 vs 16.5%; *P*<0.001). In addition, a significantly greater proportion of patients receiving colesevelam achieved either a reduction in HbA_{1c} ≥0.7% or a reduction in FPG ≥30 mg/dL by trial end (47.5 vs 32.1%; *P*=0.001). Significant LSM percent treatment differences in LDL-C, non-HDL-C, TG, TC, apo A-I and apo B were observed with colesevelam compared to placebo (*P*<0.001 for all). Significant LSM treatment differences between colesevelam and placebo were observed in the ratios of TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C and apo B/apo A-I (*P*≤0.003 for all). There was a nonsignificant LSM treatment difference between colesevelam and placebo in hsCRP levels (*P*=0.063).
Goldberg et al[35] Colesevelam 3.75 g/day vs placebo	DB, MC, PC, PG, PRO, RCT Patients 18 to 75 years of age with type 2 diabetes inadequately	N=287 16 weeks	Primary: Mean change from baseline in HbA_{1c} Secondary: Mean change in	Primary: The LSM change in HbA_{1c} level from baseline at week 16 was -0.41 and 0.09% with colesevelam and placebo, resulting in a treatment difference of -0.50% (*P*<0.001) Secondary: A numerically greater reduction in FPG level from baseline to week 16 was

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
All patients entered a 2 week, SB, placebo run-in period.	controlled (HbA_{1c} 7.5 to 9.5%) with insulin alone or in combination with oral antidiabetic agents, receiving a stable dose of insulin for ≥6 weeks and a C-peptide >0.5 ng/mL, LDL-C ≥60 mg/dL and TG ≤500 mg/dL		FPG and fructosamine from baseline to weeks four, eight and 16; arbitrary predefined assessment of glycemic control response; lipid profile	observed with colesevelam compared to placebo (treatment difference, -14.6 mg/dL; *P*=0.08); however, colesevelam, compared to placebo, significantly reduced FPG level at weeks four, eight and 16 (-15.1, -17.2 and -23.6 mg/dL, respectively; *P* values not reported). Colesevelam significantly reduced mean fructosamine levels from baseline to weeks four, eight and 16 compared to placebo (LSM treatment difference, -21.7 µmol/L; *P*<0.001 at week 16). Seventy (48.6%) and 43 (31.6%) patients receiving colesevelam and placebo had glycemic control response (*P*=0.004). More than twice as many patients receiving colesevelam had a reduction in the HbA_{1c} level ≥0.7% compared to those receiving placebo (34.7 vs 14.0%; *P*<0.001). No significant difference was observed in the percentage of patients achieving a reduction in FPG level ≥30 mg/dL. Colesevelam reduced LDL-C to a significantly greater percentage compared to placebo at week 16 (*P*<0.001). A significant increase in TG was also observed (*P*<0.001). Colesevelam also significantly reduced apo B (*P*=0.04), but did not result in a significant increase in apo A-I after 16 weeks. Colesevelam resulted in a significant decrease in LDL-C/HDL-C and apo B/apo A-I but not in the TC/HDL-C or non-HDL-C/HDL-C ratios (*P* values not reported).
Jialal et al[36] Colesevelam vs placebo All patients received their established antidiabetes therapy.	Post-hoc, pooled analysis of 3 RCTs Patients with type 2 diabetes	N=1,018 Not reported	Primary: Glycemic and lipid effects Secondary: Glycemic and lipid effects in colesevelam monotherapy and combination therapy	Primary: By trial end, mean HbA_{1c} was significantly reduced with colesevelam compared to placebo (treatment difference, -0.54%; *P*<0.0001). Mean FPG was significantly reduced with colesevelam compared to placebo (treatment difference, -15.1 mg/dL; *P*<0.0001). Colesevelam achieved significant reductions in both TC and LDL-C compared to placebo (treatment difference, -5.15 and -15.30%; *P*<0.0001). Median TG was significantly increased with colesevelam compared to placebo (treatment difference, 15.0%; *P*<0.0001). Mean non-HDL-C and apo B levels were also significantly reduced with colesevelam compared to placebo (treatment difference, -6.80 and -6.60%; *P*<0.0001). No significant effect was achieved on mean HDL-C levels (treatment difference, 0.02%; *P*

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				value not reported), but mean apo A-I levels increased significantly with colesevelam (treatment difference, 2.8%; *P*<0.0001). Median levels of hsCRP were also significantly reduced with colesevelam compared to placebo (treatment difference, -0.4 mg/L; *P*=0.0009). Secondary: The effects of colesevelam that were observed for the total group was similar in those who were receiving colesevelam as monotherapy or as a combination therapy with regard to significant reductions in HbA_{1c} (treatment difference, -0.63 and -0.48%; *P*<0.0001 for both), FPG (-12.7 and -16.8 mg/dL; *P*<0.0001 for both) and LDL-C (-12.9 and -16.8%; *P*<0.0001 for both). For patients receiving colesevelam as monotherapy, median TG levels significantly increased (treatment difference, 12.3%; *P*=0.0013). There was no significant change in TC, non-HDL-C, apo B and hsCRP levels (treatment difference, -4.84%, -6.17%, -4.98% and -0.2 mg/L; *P*=0.003, *P*=0.005, *P*=0.009 and *P* value not reported). For colesevelam as combination therapy, TG levels significantly increased compared to placebo (treatment difference, 16.6%; *P*<0.0001), while TC, non-HDL-C and apo B levels significantly reduced (treatment difference, -5.4, -7.2 and -7.7%; *P*<0.0001 for all). Apo A-I levels significantly increased and hsCRP significantly decreased with colesevelam as combination therapy (treatment difference, 3.4% and -0.5 mg/L; *P*<0.0001 and *P*=0.0027).
Henry et al[37] Colesevelam 3.75 g/day vs placebo	DB, MC, PC, PG, RCT Patients 18 to 75 years of age with type 2 diabetes mellitus for ≥3 months with an HbA_{1c} of ≥7.5% and a BMI 25 to 45	N=30 12 weeks	Primary: Change in EGO and peripheral GDR from baseline Secondary: Change from baseline in Matsuda Index,	Primary: After 12 weeks of treatment, the mean change from baseline in EGO was minimal in both the placebo group and the colesevelam group (-0.02 vs -0.06 mg/kg/min, respectively; *P*=0.581). At 12 weeks, the change in GDR from baseline was not significantly different between placebo and colesevelam (*P*>0.05). Secondary: At week 12, the mean change from baseline in Matsuda index was 0.04

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	kg/m^2		$Hb_{A1c,}$ and FPG	$[(mg/dL)(mIU/mL)]^{-1}$ with placebo and −0.26 $[(mg/dL)(mIU/mL)]^{-1}$ with colesevelam (*P*=0.324). The change in Hb_{A1c} following 12 weeks of treatment was 0.16% in the placebo group compared to -0.29% with colesevelam; however, the difference was not statistically significant (*P*=0.229). The mean change in FPG from baseline to week 12 was 13.4 mg/dL with placebo and -2.9 mg/dL with colesevelam; however, the difference was not statistically significant (*P*=0.502).
Beysen et al[38] Colesevelam 3.75 g/day vs placebo	DB, MC, PC, PG, RCT Patients with type 2 diabetes treated with diet and exercise, metformin, a sulfonylurea, or a combination of these treatments	N=60 12 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Change from baseline in FPG, GLP-1, fasting insulin, GIP, glucagon, HOMA-B, HOMA-IR, fasting LDL-C and HDL-C	Primary: There was a statistically significant reduction in Hb_{A1c} with colesevelam compared to placebo at 12 weeks (treatment difference, -0.6%; *P*<0.01). Secondary: Colesevelam was associated with a significant improvement in FPG compared to placebo at 12 weeks (treatment difference, -1.28 mmol/L; *P*<0.05). Colesevelam increased fasting plasma total GLP-1 concentrations compared to placebo (treatment difference, 10 pmol/L; *P*<0.05). No treatment differences were seen for fasting insulin, GIP, glucagon concentrations or glucagon to insulin ratio. Colesevelam significantly improved beta cell function (HOMA-B) compared to placebo (treatment difference, 18%; *P*<0.01) but not insulin sensitivity (HOMA-IR). Within the colesevelam group, fasting LDL cholesterol decreased and fasting triacylglycerol increased; however these changes were not statistically significant compared to placebo. No treatment effects were seen for fasting total cholesterol or HDL cholesterol.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Goldberg et al[39] Colesevelam 3.75 g/day plus metformin 1,700 mg/day vs metformin 1,700 mg/day plus placebo	DB, MC, PC, PG, RCT Adult patients with type 2 diabetes, an Hb_{A1c} of 6.5 to 10.0%, LDL-C levels ≥100 mg/dL, and triglyceride levels <500 mg/dL	N=286 16 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Change and percent change in lipids, apolipoproteins, and lipoprotein particle concentration and size	Primary: Treatment with metformin plus colesevelam resulted in a significant reduction in Hb_{A1c} after 16 weeks (mean treatment difference: -0.3%; *P*=0.0035). Secondary: Combination therapy with metformin plus colesevelam significantly reduced LDL-C (-16.3%), total cholesterol (-6.1%), non–HDL-C (-8.3%) and apolipoprotein B levels (-8.0%) compared to metformin plus placebo (*P*<0.001 for all). Patients treated with metformin plus colesevelam experienced a significant increase in TG (median treatment difference: 18.6%) and apo A-1 levels (mean treatment difference: 4.4%) compared to patients receiving metformin plus placebo (*P*<0.001 for both). Patients receiving combination therapy with metformin plus colesevelam experienced a significant increase in both medium and large VLDL particle concentration compared to patients randomized to receive metformin plus placebo (*P*<0.01 for both); however, there was no statistically significant difference between the groups with regard to small VLDL particles. Total HDL was increased from baseline in both treatment groups at week 16; however, the increase was significantly greater with metformin plus colesevelam compared to metformin plus placebo in terms of both absolute change (*P*=0.03) and percent change (*P*=0.01).
Rigby et al (abstract)[40] Colesevelam 3.75 g/day vs rosiglitazone 4 mg/day vs	MC, OL Adult patients with inadequately controlled type 2 diabetes (HbA_{1c} 7 to 10%) on a stable metformin regimen (1,500 to 2,550 mg/day for ≥3	N=169 16 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Change from baseline in LDL-C	Primary: The LSM reductions in HbA_{1c} from baseline were -0.3 (*P*<0.031), -0.6 (*P*<0.001) and -0.4% (*P*<0.008) with colesevelam, rosiglitazone and sitagliptin. At trial end, 17.9, 35.2 and 27.3% of patients receiving colesevelam, rosiglitazone and sitagliptin achieved an HbA_{1c} of <7% (*P* values not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
sitagliptin 100 mg/day All patients continued their existing metformin therapies.	months)			Compared to baseline, colesevelam significantly reduced LDL-C (11.6%), whereas levels were significantly increased with rosiglitazone (7.8%) and sitagliptin (7.7%), respectively. At trial end, 42.3, 23.5 and 24.5% of patients receiving colesevelam, rosiglitazone and sitagliptin achieved an LDL-C of <100 mg/dL (*P* values not reported).
Ooi et al[41] Colesevelam with or without other oral hypoglycemic agents vs placebo with or without other oral hypoglycemic agents	SR (6 RCTs) Patients ≥18 years of age with type 2 diabetes and an LDL-C that warrants addition of an antihyperlipidemic agent	N=1,450 Up to 26 weeks	Primary: HbA_{1c}, fasting and postprandial glucose levels, morbidity and adverse events Secondary: Mortality (all-cause and diabetes-related), changes in lipid profile, obesity measures, changes in blood insulin, C-peptide or insulin resistance and functional outcomes	Primary: *Metabolic control* The addition of colesevelam to other hypoglycemic agents demonstrated a significant reduction in HbA_{1c} compared to placebo (mean difference, -0.5%; 95% CI, -0.6 to -0.4; *P*<0.00001). In a single trial comparing colesevelam to placebo, there was no statistically significant difference in the reduction in HbA_{1c} between colesevelam and placebo (*P* value not reported). Colesevelam with add-on hypoglycemic agents demonstrated a significant reduction in FPG compared to placebo (mean difference, -15 mg/dL; 95% CI, -22 to -8; *P*<0.0001). *Colesevelam plus metformin monotherapy with/without other antidiabetic agents vs placebo plus metformin with/without oral antidiabetic agents* For FPG, the mean difference between the groups was -16 mg/dL (95% CI -28 to -4; *P*<0.01), favoring the addition of colesevelam compared to placebo. The mean HbA_{1c} difference was also significant (mean difference, -0.6%; 95% CI, -0.8 to -0.4; *P*<0.0001) in favor of colesevelam. *Colesevelam plus sulfonylurea monotherapy or sulfonylurea plus oral antidiabetic agents vs placebo plus sulfonylurea monotherapy or sulfonylurea plus oral antidiabetic agents* There were significant improvements in favor of colesevelam compared to placebo with regard to FPG (mean difference, -13 mg/dL; 95% CI, -23 to -2; *P*<0.05) and HbA_{1c} (mean difference, -0.6%; 95% CI, -0.8 to -0.4; *P*<0.00001). *Colesevelam plus insulin monotherapy or insulin plus oral antidiabetic agents vs placebo plus insulin monotherapy or insulin plus oral antidiabetic agents*

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				Significant improvements were reported with colesevelam compared to placebo with regard to FPG (mean difference, -24 mg/dL; 95% CI, -42 to -6; *P*<0.05) and HbA_{1c} (mean difference, -0.5%; 95% CI, -0.7 to -0.3; *P*<0.00001). *Colesevelam plus metformin vs placebo plus metformin* When added to metformin, colesevelam significantly reduced HbA_{1c} compared to placebo (mean difference, -0.3%; 95% CI, -0.5 to -0.2; *P*<0.0001). There was no significant treatment difference for FPG at 16 weeks in one study (mean difference, -6.0; 95% CI, -13.0 to 0.0; *P*<0.2370). *Colesevelam plus antidiabetic agents vs placebo plus antidiabetic agents* For FPG, the mean difference between the treatments was -7 mg/dL (95% CI, -26 to -12; *P*>0.05) which was not significant. The mean HbA_{1c} difference (-0.5%; 95% CI, -0.9 to -0.1; *P*<0.006) favored treatment with colesevelam. *Morbidity* There were no publications reporting data on morbidity outcomes. *Adverse events* Most events were mild to moderate gastrointestinal symptoms such as constipation and dyspepsia. Discontinuation due to adverse events was not significantly different between colesevelam only or colesevelam and other antidiabetic agents (RR, 1.57; 95% CI, 0.89 to 2.75; *P*=0.12). Only three trials reported mild hypoglycemic episodes, with no differences in severe or nocturnal hypoglycemia reported in all these trials. Secondary: *Mortality* There were no publications reporting data on mortality outcomes. *Lipid profile* Colesevelam with add-on hypoglycemic agents demonstrated a statistically significant reduction in LDL-C compared to placebo (mean difference, -13 mg/dL; 95% CI, -17 to -9; *P*<0.00001). There was also a significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				reduction in triglyceride levels (*P* value not reported). Secondary data for LDL-C, non-HDL-C, triglycerides, apo A-1 and apo B suggested statistically significant changes favoring colesevelam combination with other oral antidiabetic agents. *Obesity measures* There were no publications reporting data on changes in body weight, BMI, waist circumference, waist-to-hip ratio or total body fat. *Changes in blood insulin, C-peptide levels or insulin resistance* There were no statistically significant changes in these parameters between the patients treated with colesevelam compared to placebo. Colesevelam plus metformin with or without other oral antidiabetic agents vs placebo plus metformin with or without other antidiabetic agents did not demonstrate any statistical significant mean changes in the levels of fasting C-peptide, fasting insulin and homeostasis model assessment Index. *Functional outcomes* There were no publications reporting data on functional outcomes. *Health-related quality of life* There were no publications reporting data on health-related quality of life.

Drug regimen abbreviations: BID=twice daily, TID=three times daily
Study abbreviations: CI=confidence interval, DB=double-blind, ES=extension study, MA=meta-analysis, MC=multicenter, OL=open label, PC=placebo-controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, RR, relative risk, SB=single-blind, SR=systematic review
Miscellaneous abbreviations: apo A-1=apolipoprotein A-1, apo B=apolipoprotein B, BMI=body mass index, CAD=coronary artery disease, CHD=coronary heart disease, CRP=C-reactive protein, EGO=endogenous glucose output, GDR=glucose disposal rate, GIP=glucose-dependent insulinotropic peptide, GLP-1=glucagon like peptide-1, FPG=fasting plasma glucose, HOMA-B= homeostasis model assessment of beta cell function, HOMA-IR= homeostasis model assessment of insulin resistance, HbA_{1c}=glycosylated hemoglobin, HDL-C=high density lipoprotein cholesterol, hsCRP=high-sensitivity C-reactive protein, IL6=interleukin 6, LDL-C=low density lipoprotein cholesterol, LSM=least squares mean, MI=myocardial infarction, NCEP=National Cholesterol Education Program, TC=total cholesterol, TG=triglycerides, VLDL= very-low-density lipoprotein

Special Populations

Table 5. Special Populations[3-7]

Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
Cholestyramine	No dosage adjustment required in the elderly. Safety and efficacy in children have not been established.*	No dosage adjustment required.	Not reported	C	No; use with caution.
Colesevelam	No dosage adjustment required in the elderly. Safety and efficacy in children <10 years of age for the treatment of heterozygous familial hyper-cholesterolemia have not been established. Safety and efficacy in children for adjunct treatment of type 2 diabetes have not been established.	No dosage adjustment required.	No dosage adjustment required.	B	No
Colestipol	No dosage adjustment required in the elderly. Safety and efficacy in children have not been established.	Not reported	Not reported	C	Unknown; use with caution.

*A usual pediatric dose of 240 mg/kg/day administered in two to three divided doses is recommended.

Adverse Drug Events

Table 6. Adverse Drug Events[3-7]

Adverse Event(s)	Cholestyramine	Colesevelam	Colestipol
Body as a Whole			
Accidental injury	-	4	-
Asthenia/weakness	-	4	✔
Back pain	-	3	✔
Fatigue	-	-	✔
Flu syndrome	-	3	-
Infection	-	10	-
Pain	-	5	-
Rash	✔	-	✔
Swelling of hands and feet	-	-	✔
Vitamin A deficiency	✔	-	-
Vitamin D deficiency	✔	-	-
Cardiovascular			
Angina	-	-	✔

Adverse Event(s)	Cholestyramine	Colesevelam	Colestipol
Chest pain	-	-	✔
Tachycardia	-	-	✔
Central Nervous System			
Dizziness/light-headedness	✔	-	✔
Headache	✔	6	✔
Insomnia	-	-	✔
Migraine	-	-	✔
Gastrointestinal			
Abdominal pain/discomfort	✔	5	✔
Anorexia	✔	-	✔
Constipation	✔	11	✔
Diarrhea	✔	5	✔
Dyspepsia	-	8	✔
Eructation	✔	-	-
Flatulence	✔	12	✔
Nausea	✔	4	✔
Steatorrhea	✔	-	-
Vomiting	✔	-	-
Hematological			
Hypoprothrombinemia associated with vitamin K deficiency	✔	-	-
Musculoskeletal			
Myalgia	-	2	✔
Osteoporosis	✔	-	-
Respiratory			
Cough increased	-	2	-
Pharyngitis	-	3	-
Rhinitis	-	3	-
Shortness of breath	-	-	✔
Sinusitis	-	2	-
Laboratory Test Abnormalities			
Abnormal liver function tests (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase)	✔	-	✔
Changes in triglyceride levels	✔	✔	✔

-Event not reported or incidence <1%.
✔ Percent not specified.

Contraindications/Precautions

Cholestyramine and colestipol are contraindicated in patients with hypersensitivity to bile acid sequestering resins or any component of the formulation or in bowel obstruction.[3-6] Cholestyramine is also contraindicated in complete biliary obstruction.[3,4] Colesevelam is contraindicated in a history of bowel obstruction, serum triglycerides >500 mg/dL and a history of hypertriglyceridemia-induced pancreatitis.[7]

Administration of bile acid sequestrants may produce or exacerbate constipation problems, and fecal impaction may develop. In addition, hemorrhoids may be worsened. Use of bile acid sequestrants is not recommended in patients with gastroparesis, other severe gastrointestinal motility disorders or a history of major gastrointestinal tract surgery. Patients with dysphagia or swallowing disorders should administer the oral suspensions of bile acid sequestrants.[3-7]

Administration of bile acid sequestrants with fat soluble vitamins and folic acid may interfere with absorption of these agents. In addition, caution should be exercised in patients susceptible of fat soluble vitamin deficiencies.[3-7]

Chronic administration of cholestyramine and colestipol, especially in high doses, may be associated with bleeding problems.[3-6]

Secondary causes of hyperlipidemia should be ruled out prior to therapy with cholestyramine. Caution should be exercised in the treatment of patients with serum triglycerides >300 mg/dL as therapy may cause increased concentrations. Therapy should be discontinued if triglyceride concentrations exceed 500 mg/dL or if hypertriglyceridemia-induced pancreatitis occurs.[3-7]

Colesevelam is not indicated for the management of type 1 diabetes, particularly in the acute management. It is also not indicated in type 2 diabetes as monotherapy and must be used as adjunct to diet, exercise and glycemic control with insulin or oral antidiabetic agents. Combination with dipeptidyl peptidase 4 inhibitors or thiazolidinediones has not been extensively evaluated.[7]

Questran Light® and some colesevelam- and colestipol-containing products contain phenylalanine.[3-7]

Drug Interactions

Table 7. Drug-Drug Interactions[3-7]

Drugs	Interaction	Mechanism
Bile acid sequestrants (cholestyramine, colestipol)	Corticosteroids	A decrease in the therapeutic effect of corticosteroids may occur.
Bile acid sequestrants (cholestyramine, colestipol)	Digoxin	A decrease in the bioavailability of digoxin may occur.
Bile acid sequestrants (cholestyramine, colestipol)	Loop diuretics	A decrease in the therapeutic effect of loop diuretics may occur.
Bile acid sequestrants (cholestyramine, colesevelam)	Thyroid hormones	A decrease in the therapeutic effect of thyroid hormones may occur.
Bile acid sequestrants (cholestyramine)	Anticoagulants	A decrease in the anticoagulant effect of anticoagulants may occur.
Bile acid sequestrants (cholestyramine)	Deferasirox	A decrease in the therapeutic effect of deferasirox may occur.
Bile acid sequestrants (cholestyramine)	Valproic acid	A decrease in the therapeutic effect of valproic acid may occur.

Dosage and Administration

Table 8. Dosing and Administration[3-7]

Generic Name	Adult Dose	Pediatric Dose	Availability
Cholestyramine	Adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia who do not respond adequately to diet:* Powder: initial, 4 g QD or BID; maintenance, 8 or 16 g/day administered in two divided doses†; maximum, 24 g/day (Prevalite®) Relief of pruritus associated with partial biliary obstruction:‡ Powder: initial, 4 g QD or BID; maintenance, 8 or 16 g/day administered in two divided doses†; maximum, 24 g/day (Prevalite®)	Safety and efficacy in children have not been established.§	Powder: 4 g

Generic Name	Adult Dose	Pediatric Dose	Availability
Colesevelam	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: Powder: 3.75 g QD Tablet: 3.75 g QD or 1.875 g BID Adjunct to diet and exercise to reduce elevated LDL-C in adults with primary hyperlipidemia as monotherapy or in combination with a statin: Powder: 3.75 g QD Tablet: 3.75 g QD or 1.875 g BID	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: Safety and efficacy in children have not been established. Monotherapy or in combination with a statin to reduce LDL-C in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hyper-cholesterolemia:‖ Powder: 3.75 g QD	Powder: 3.75 g Tablet: 625 mg
Colestipol	Adjunctive therapy to diet for the reduction of elevated serum total cholesterol and LDL-C in patients with primary hypercholesterolemia who do not respond adequately to diet:# Granules, powder: initial, 5 g (one packet or level teaspoon) QD or BID; maintenance, increase dose by 5 g QD or BID at one or two month intervals to a maintenance dose between 5 to 30 g/day administered QD or in divided doses Tablet: initial, 2 g QD or BID; maintenance, increase dose by 2 g QD or BID at one or two month intervals to a maintenance dose between 2 to 16 g/day administered QD or in divided doses	Safety and efficacy in children have not been established.	Granules: 5 g Powder: 5 g Tablet: 1 g

BID=twice-daily, LDL-C=low density lipoprotein cholesterol, QD=once-daily
*May be useful to lower low density lipoprotein cholesterol (LDL-C) in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
†Although the recommended dosing schedule is twice-daily, Prevalite® may be administered in 1 to 6 g doses per day.
‡Has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit elevated cholesterol as part of their disease.
§A usual pediatric dose of 240 mg/kg/day administered in two to three divided doses is recommended.
‖If after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present in the pediatric patient.
#May be useful to lower LDL-C in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.

Clinical Guidelines

Current guidelines are summarized in Table 9. The guidelines addressing the management of hypercholesterolemia are presented globally, addressing the role of various medication classes in the management of this disease.

Table 9. Clinical Guidelines

Clinical Guideline	Recommendations
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[8]	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statin) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrant, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrant (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrant and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u>

Clinical Guideline	Recommendations
	• TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002)**[1]	General recommendations • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made. • Initiate LDL lowering drug therapy with a statin, bile acid sequestrant or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. Statins • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. Bile acid sequestrant • Bile acid sequestrant should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy and for patients needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrant should be considered in combination therapy with statins in patients with very high LDL-C levels. Nicotinic acid • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels, and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. Fibric acid derivatives (fibrates) • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with

Clinical Guideline	Recommendations
	dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. Omega-3 fatty acids • Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1 to 2 g/day) in the form of fish, fish oils or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Heart Association/American College of Cardiology/National Heart, Lung, and Blood Institute: **American Heart Association/American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)**[42]	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis. • If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrant and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable. • The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrant,

Clinical Guideline	Recommendations
	and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2011)**[9]	Clinical highlights • Initiate a statin with patients who have a history of CHD or CHD risk equivalents. • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up. • An LDL goal <70 mg/dL can be considered for patients with established coronary artery disease, non-cardiac atherosclerosis, or coronary artery disease equivalent. Ongoing drug therapy • The use of statin therapy is recommended in patients with established CHD or CHD risk equivalents (includes occlusive carotid disease, peripheral vascular disease, abdominal aortic aneurysm, and diabetes). • Combination therapy can be considered on an individual basis. • No primary prevention trials have addressed pharmacologic lipid treatment in patients at low risk for CHD, and there is no evidence to support drug treatment in this population. • Primary prevention trials of pharmacologic lipid-lowering have not shown a decrease in mortality, although most have shown about a 30% reduction in CHD events. Monotherapy • Patients with risk factors for CHD but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of CHD. • Patients with a history of CHD often benefit from statin therapy, and trials have consistently shown a decrease in risk of death from CHD. • The use of statin therapy is recommended in patients with established CHD or CHD risk equivalents (includes occlusive carotid disease, peripheral vascular disease, abdominal aortic aneurysm, and diabetes). • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out. • Incidence of muscle symptoms or signs is the most prevalent and important adverse effect of statin therapy. • Specific statin and dose should be selected based on cost and amount of lipid-lowering required.

Clinical Guideline	Recommendations
	• If patients are unable to take a statin, then bile acid sequestrant, niacin, fibric acid derivatives or fibrates, and ezetimibe are available. • Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia. • Long-term use of niacin is usually limited for many patients due to side effects (e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc). • Combination therapy with niacin and a statin may increase the risk of myopathy based on early experience with lovastatin. • Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not proven for fenofibrate). • Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease. • The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin. • The short-term tolerability of ezetimibe is similar to placebo, and the long-term safety is unknown. • Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin. • Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after. <u>Combination therapy</u> • It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe. o A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy. o No published clinical trial to date has evaluated the clinical benefit of combination therapy with a statin and niacin on vascular events. o The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular

Clinical Guideline	Recommendations
	endpoints. • Combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy. • Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further trials indicate what groups of patients might benefit. • There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins. • No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy. Lifestyle modifications • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a diet and exercise program for a reasonable amount of time to determine whether their LDL-C level is lowered to the target range. • A diet low saturated and trans fats, and high in soluble fiber, with consideration given to adding two grams of plant sterol/stanol is recommended. • Vitamin E supplementation should not be used. • Light to moderate consumption of alcohol may lower CHD rates. • Omega-3 fatty acids should be recommended in patients with dyslipidemia (one gram of EPA/DHA by capsule supplement, or by eating at least two servings per week of fatty fish).
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)**[43]	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2012)**[10]	Drugs • Currently available lipid-lowering drugs include statins, fibrates, bile acid sequestrants, niacin, and selective cholesterol absorption inhibitors (e.g., ezetimibe). • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with

Clinical Guideline	Recommendations
	hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not used as monotherapy to decrease LDL-C. • Bile acid sequestrants also decrease TC and LDL-C, but tend to increase TG. • Fibrates and niacin are used primarily for TG lowering and increasing HDL-C, while fish oils (omega-3 fatty acids) in doses of 2 to 4 g/day are used for TG lowering. • Fibrates are the drugs of choice for patients with severely elevated TG, and prescription omega-3 fatty acids might be added if elevated TG is not decreased adequately. Drug combinations • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • Combinations of a statin and a bile acid sequestrants or a combination of a statin and ezetimibe can be used for greater reduction in LDL-C than can be achieved with either agent used as monotherapy. • Another advantage of combination therapy is that lower doses of statins can be utilized, thus reducing the risk of adverse events associated with high dose statin therapy. However, statins should be used in the highest tolerable dose to reach LDL-C target level before combination therapy is initiated. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis (2009)**[11]	Therapy for primary biliary cirrhosis (PBC) • Ursodeoxycholic acid in a dose of 13 to 15 mg/kg/day orally is recommended for patients with PBC who have abnormal liver enzyme values regardless of histologic stage. • For patients requiring bile acid sequestrants, ursodeoxycholic acid should be given two to four hours before or after ingestion. • Bile acid sequestrants should be used as initial therapy for patients with PBC who have pruritus. • The following agents can be used for pruritus refractory to bile acid sequestrants: rifampicin, oral opiate antagonists (such as naltrexone) and sertraline. • Management of dry eyes can include the following: o Artificial tears as initial therapy. o Pilocarpine or cevimeline can be used in patients refractory to artificial tears. o Cyclosporine ophthalmic emulsion can be used in those refractory to other agents, preferably under the supervision of

Clinical Guideline	Recommendations
	an ophthalmologist. • The following therapies should be reserved for xerostomia and dysphagia o Saliva substitutes can be tried. o Pilocarpine or cevimeline can be used if patients remain symptomatic despite saliva substitutes. o Moisturizers can be given for vaginal dryness.
American Association of Clinical Endocrinologists: **Guidelines for the Management of Dyslipidemia and Prevention of Atherosclerosis (2012)**[44]	• Aggressive lipid-modifying therapy is recommended to lower LDL-C to <100 mg/dL in patients with average or elevated LDL-C. This has been shown to reduce vascular mortality in patients at high risk. • An LDL-C goal <70 mg/dL is recommended as an appropriate goal for *all* patients with established coronary artery disease. Current evidence indicates that LDL-C can be aggressively lowered with statin therapy regardless of baseline levels and suggests that there is no threshold below which LDL-C lowering ceases to be effective. • Patients for whom aggressive therapy is recommended: o Patients undergoing coronary artery bypass graft. o Patients with acute coronary syndrome (ACS). o Certain healthy and functional older patients at high risk. • Statins are the drug of choice for LDL-C reduction on the basis of findings from morbidity and mortality outcome trials. Agents currently available are atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin. • Fibrates are recommended for treatment of severe hypertriglyceridemia (triglycerides >500 mg/dL). Adjunct use of 2 to 4 g of omega 3 acids can be used, if necessary, to achieve satisfactory triglyceride lowering. • Niacin is recommended for reducing triglycerides, increasing HDL-C, and reducing LDL-C. Adjunct use of 2 to 4 g of omega-3 fish oil can be used, if necessary, to achieve satisfactory triglyceride lowering. • Bile acid sequestrants are recommended for reducing LDL-C and apolipoprotein B and modestly increasing HDL-C, but they may increase triglycerides. Bile acid sequestrants have a glucose-lowering effect; colesevelam is now also approved for treatment of type 2 diabetes. Available agents in this drug class are cholestyramine, colestipol, and colesevelam. • Cholesterol absorption inhibitors are effective as monotherapy in reducing LDL-C and apolipoprotein B. Combination therapy with statins is recommended because current research indicates that this enhances these benefits and further improves the beneficial effects of statins on triglycerides and HDL-C. It is uncertain whether cholesterol absorption inhibitor therapy has a direct benefit on reducing cardiovascular events. • Combination therapy be considered in the following circumstances: o When the cholesterol level is markedly increased and monotherapy does not achieve the therapeutic goal. o When mixed dyslipidemia is present. o Niacin or fibrates in combination with statins may be appropriate options for many patients with hypertriglyceridemia and associated low HDL-C. o To reduce the risk of dosage-related adverse effects. • Recommendations for lipid management in children include: o Colesevelam has been approved for patients older than 8

Clinical Guideline	Recommendations
	years. o Atorvastatin, lovastatin, pravastatin, simvastatin, and rosuvastatin have been approved for the treatment of familial hypercholesterolemia in patients 10 years or older. Cholestyramine may also be used in children.

Conclusions

The bile acid sequestrants are a class of medications whose major function is to decrease low density lipoprotein cholesterol (LDL-C) levels. These agents work by binding to bile acids in the intestine through anion exchange causing an interruption of the reabsorption of bile acids. This reduction in bile acids leads to feedback regulation on the conversion of cholesterol to bile acids. Currently, three bile acid sequestrants are available: cholestyramine (Prevalite®, Questran® and Questran Light®), colesevelam (Welchol®) and colestipol (Colestid® and Flavored Colestid®). All agents are typically administered once or twice daily, and only cholestyramine and colestipol are available generically. Colesevelam is more potent compared to either cholestyramine or colestipol, and colesevelam may be more easily administered and better tolerated compared to the other agents.[1,2]

The bile acid sequestrants are all Food and Drug Administration (FDA)-approved for adjunct treatment in patients with hypercholesterolemia.[3-7] Cholestyramine is also FDA-approved for relief of pruritus associated with partial biliary obstruction.[3,4] In addition, colesevelam is also FDA-approved as monotherapy in children 10 to 17 years of age for the treatment of heterozygous familial hypercholesterolemia, and as adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes.[7]

Clinical trial data consistently demonstrate the “superiority” of the bile acid sequestrants over placebo for the management of hyperlidpidemia.[16-25] In line with current clinical guidelines, results demonstrate that the addition of a bile acid sequestrant to another lipid lowering agent has the potential to produce further reductions in LDL-C levels compared to monotherapy with either of the agents.[20-27] In addition, treatment with cholestyramine has demonstrated mortality benefit in patients in reducing the risk of coronary heart disease death and/or nonfatal myocardial infarction.[28,29] As add on therapy to existing antidiabetic regiments, colesevelam achieves significant reductions in glycosylated hemoglobin compared to placebo.[30-40]

Therapeutic lifestyle changes, including diet, exercise and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia.[1,8,9] When LDL lowering is required, initial treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), a bile acid sequestrant or niacin is recommended; however, the statins are considered first line therapy for decreasing LDL-C levels.[1,8-10] If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or niacin should be considered.[1] Statins are also considered first line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy.[8] The bile acid sequestrants are recognized as the therapy of choice for the management of pruritus associated with primary biliary cirrhosis.[11]

References

1. National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, 2002 [guideline on the internet]. NCEP. 2002 [cited 2013 Jul 22]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
2. Rosenson RS. Lipid lowering with drugs other than statins and fibrates. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2013 [cited 2013 Jul 22]. Available from: http://www.utdol.com/utd/index.do.
3. Prevalite® [package insert]. Minneapolis (MN): Upsher-Smith Laboratories, Inc.; 1998 Jan.
4. Questran® and Questran Light® [package insert]. Princeton (NJ): Bristol-Meyers Squibb Company; 2006 May.
5. Flavored Colestid® [package insert]. New York (NY): Pharmacia and Upjohn Company; 2013 Jul.
6. Colestid® [package insert]. New York (NY): Pharmacia and Upjohn Company; 2013 Jul.
7. Welchol® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2012 Jul.
8. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
9. Institute for Clinical Systems Improvement (ISCI). Healthcare guideline: lipid management in adults 12th ed., 2011 [guideline on the Internet]. ICSI. 2011 [cited 2013 Jul 22]. Available from: http://www.icsi.org/lipid_management_3/lipid_management_in_adults_4.html.
10. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2012 Aug;19(4):585-667.
11. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergassa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
12. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr;19(2):327-36.
13. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013 Jan;36 Suppl 1:S11-66.
14. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2013 Jul 22]. Available from: http://www.thomsonhc.com/.
15. Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study of the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010;10(5):306-14.
16. Stein EA, Marias AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231-6.
17. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006 Apr;185(2):327-30.
18. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15;97(8):1198-205.
19. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct;76(10):971-82.
20. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AFH, Imholz BPM, Durrington PN, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32(4):615-25.

21. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40.
22. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
23. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 Oct;158(2):407-16.
24. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia (abstract). Clin Cardiol. 2001 Jun;24(6):467-74.
25. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr;110(5):352-60.
26. Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med. 1998 May;243(5):373-80.
27. Ballantyne C, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov;26(11):1855-64.
28. No authors listed. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan;251(3):351-64.
29. No authors listed. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan;251(3):365-74.
30. Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res. 2010;42:23-30.
31. Zieve FJ, Kalin MF, Schwartz S, Jones MR, Bailey WL. Results of the Glucose-Lowering Effect of Welchol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83.
32. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes (abstract). Endocr Pract. 2010 Jul-Aug;16(4):629-40.
33. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med. 2008;168(18):1975-83.
34. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-84.
35. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531-40.
36. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009;7(3):255-8.
37. Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Jan;14(1):40-6.
38. Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomized controlled study. Diabetologia. 2012 Feb;55(2):432-42.

39. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol. 2012 Jul;6(4):318-24.
40. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy (abstract). Endocr Pract. 2010 Jan-Feb;16(1):53-63.
41. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009361.
42. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
43. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.
44. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78.